Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does FOSAPREPITANT DIMEGLUMINE Cause Injection site erythema? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Injection site erythema have been filed in association with FOSAPREPITANT DIMEGLUMINE (Fosaprepitant). This represents 1.1% of all adverse event reports for FOSAPREPITANT DIMEGLUMINE.

10
Reports of Injection site erythema with FOSAPREPITANT DIMEGLUMINE
1.1%
of all FOSAPREPITANT DIMEGLUMINE reports
0
Deaths
0
Hospitalizations

How Dangerous Is Injection site erythema From FOSAPREPITANT DIMEGLUMINE?

Of the 10 reports.

Is Injection site erythema Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for FOSAPREPITANT DIMEGLUMINE. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does FOSAPREPITANT DIMEGLUMINE Cause?

Dyspnoea (142) Pyrexia (136) Nausea (130) Infusion related reaction (83) Diarrhoea (80) Vomiting (71) Rash (66) Hypersensitivity (65) Stomatitis (64) Decreased appetite (62)

What Other Drugs Cause Injection site erythema?

ETANERCEPT (17,736) DUPILUMAB (8,818) ADALIMUMAB (8,563) TIRZEPATIDE (3,844) TERIPARATIDE (3,453) GLATIRAMER (2,560) IXEKIZUMAB (2,144) ENBREL (1,879) EVOLOCUMAB (1,754) HUMIRA (1,654)

Which FOSAPREPITANT DIMEGLUMINE Alternatives Have Lower Injection site erythema Risk?

FOSAPREPITANT DIMEGLUMINE vs FOSCARBIDOPA\FOSLEVODOPA FOSAPREPITANT DIMEGLUMINE vs FOSCARNET FOSAPREPITANT DIMEGLUMINE vs FOSFOMYCIN FOSAPREPITANT DIMEGLUMINE vs FOSFOMYCIN TROMETHAMINE FOSAPREPITANT DIMEGLUMINE vs FOSINOPRIL

Related Pages

FOSAPREPITANT DIMEGLUMINE Full Profile All Injection site erythema Reports All Drugs Causing Injection site erythema FOSAPREPITANT DIMEGLUMINE Demographics